Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | Pyros Pharmaceuticals receives FDA approval for infantile spasms drug | ||
Mo | Takeda, Ascentage Pharma sign option agreement for olverembatinib | ||
Fr | Quadram and SKAN partner for microbial therapies development | ||
Do | Sibylla Biotech, MD Anderson to develop cancer treatments | ||
12.06. | DoH expands research partnership with Penn Medicine | ||
11.06. | FDA grants fast track status for GC Biopharma and Novel Pharma's GC1130A | ||
10.06. | FDA accepts Eisai's sBLA for intravenous LEQEMBI to treat early Alzheimer's | ||
07.06. | PharmaCord to boost pharma services with Permira's investment | ||
06.06. | FDA grants orphan drug status to Agomab's AGMB-447 for IPF treatment | ||
05.06. | Repare Therapeutics secures FDA Fast Track designation for ovarian cancer therapy | ||
04.06. | Pfizer and Abu Dhabi partners to boost sickle cell disease research | ||
03.06. | Telix seeks BLA for TLX250-CDx aimed at kidney cancer imaging | ||
31.05. | Weave Bio secures $10m in seed funding round | ||
30.05. | ExpressionEdits secures $13m to develop protein-based therapies | ||
29.05. | Lucy Therapeutics secures $12.5m for neurological treatment development | ||
28.05. | RevolKa signs deal with Daiichi Sankyo for functional proteins | ||
27.05. | EMA validates MAA for Prolia and Xgeva (denosumab) biosimilar candidate HLX14 | ||
24.05. | Radar Therapeutics secures $13.4m to develop programmable medicines | ||
23.05. | Amneal Pharmaceuticals launches supply of Naloxone HCI Nasal Spray in US | ||
22.05. | AstraZeneca targets $80bn revenue by 2030 | ||
21.05. | Teva and Alvotech launch SIMLANDI in US for arthritis | ||
20.05. | ERS Genomics and IRBM sign deal for CRISPR technology | ||
17.05. | Sol-Gel, Beimei sign deal for TWYNEO commercialisation | ||
16.05. | Scorpius announces validation of microbial facilities | ||
15.05. | FogPharma and ARTBIO collaborate to co-develop new cancer therapies |